Journal Article

RAS Mutation Prevalence Among Patients With Metastatic Colorectal Cancer: a Meta-Analysis of Real-World Data

Mokhtar, Nadia, Toth, Erika, Skalova, Alena, Tysarowski, Andrzej, Timar, Jozsef, Gouvas, Nikolaos, Papaxoinis, George, Fabian, Pavel, Kafatos, George, Niepel, Daniela, Vosmikova, Hana, Lowe, Kimberley, Murray, Samuel, Westhead, Hal, Traugottová, Zuzana, van Krieken, J Han, Bilalis, Antonios, Trojan, Jörg, Jenkins-Anderson, Sophie, Garawin, Tamer, Wójcik, Piotr, Barugel, Mario, Molnar, Edit

2017

Overview

A confirmed wild-type RAS tumor status is commonly required for prescribing anti-EGFR treatment for metastatic colorectal cancer. This noninterventional, observational research project estimated RAS mutation prevalence from real-world sources. Aggregate RAS mutation data were collected from 12 sources in three regions. Each source was analyzed separately; pooled prevalence estimates were then derived from meta-analyses. The pooled RAS mutation prevalence from 4431 tumor samples tested for RAS mutation status was estimated to be 43.6% (95% CI: 38.8-48.5%); ranging from 33.7% (95% CI: 28.4-39.3%) to 54.1% (95% CI: 51.7-56.5%) between sources. The RAS mutation prevalence estimates varied among sources. The reasons for this are not clear and highlight the need for further research.

• Publisher: Future Medicine Ltd
• Subject: Biomarkers / Biomarkers, Tumor - genetics / Colorectal cancer / Colorectal carcinoma / Colorectal Neoplasms - epidemiology / Colorectal Neoplasms - mortality / Colorectal Neoplasms - pathology / Data collection / Epidermal growth factor receptors / Estimates / Exons / Humans / Meta-analysis / Metastases / Metastasis / Mutation / Pathology / Patients / Prevalence / Proto-Oncogene Proteins B-raf - genetics / Proto-Oncogene Proteins p21(ras) - genetics / Source studies / Survival Rate / Variables